DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop ...

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

The combination of cabozantinib and atezolizumab appeared more effective than switching ARPI therapy in patients with mCRPC and extrapelvic soft-tissue metastases.

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...

XTANDI is the first and only androgen receptor pathway inhibitor (ARPI) indicated and reimbursed in Ontario for use in patients with nmCSPC with biochemical recurrence at high risk for ...

Interdisciplinary Genitourinary Cancer Forum featured a metastatic castration resistant prostate cancer (mCRCP) session and a ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

Their study (“A TBX2-Driven Signaling Switch from Androgen Receptor to Glucocorticoid Receptor Confers Therapeutic Resistance in Prostate Cancer”), which was published in December 2024 by ...

Azolato-Bridged Dinuclear Platinum (II) Complexes Exhibit Androgen Receptor-Mediated Anti-Prostate Cancer Activity. Inorganic Chemistry, 2024; 63 (44): 20951 DOI: 10.1021/acs.inorgchem.4c01093 ...

Background: Glioblastoma is a lethal brain cancer. Clinical patterns of disease suggest that androgens influence glioblastoma risk and prognosis, and androgen receptor (AR) transcript levels and ...